YY1 was discovered to be highly expressed in various malignancies and to be important in controlling tumor cell drug resistance to cell-mediated immunotherapy, according to Emily et al. They hypothesized that YY1's function in cancer immune resistance was linked to programmed cell death ligand 1 (PD-L1) overexpression in tumor cells, and they discovered multiple signal crosstalk pathways between YY1 and PD-L1 expression regulation [47]. Here, YY1 is linked to cancer.